

Special Issue

Perioperative and Adjuvant Immunotherapy in Lung Cancer: New Strategies, Biomarkers, Patient Selection and Toxicity Management

Message from the Guest Editors

This Special Issue aims to bring together the latest clinical, translational, and real-world evidence in the following areas:

- New perioperative and adjuvant immunotherapy strategies in NSCLC.
- Patient selection for each treatment approach.
- Biomarkers to predict efficacy and/or toxicity and guide immunotherapy strategy selection.
- Combination approaches with antibody–drug conjugates (ADCs), chemotherapy, targeted therapy, or radiotherapy.
- Mechanisms of resistance and strategies to overcome them in early-stage disease.
- Management and prevention of immune-related and other treatment-related toxicities.
- Surgical considerations in patients receiving perioperative immunotherapy.
- Integration of artificial intelligence and omics-based tools for response and toxicity prediction.

We welcome original research articles, reviews, and communications addressing these topics from a clinical, translational, or multidisciplinary perspective. We look forward to your contributions to advance the field and refine the role of perioperative and adjuvant immunotherapy in lung cancer.

Guest Editors

Dr. Xabier Mielgo Rubio

Dr. Felipe Couñago

Dr. Juan Carlos Trujillo-Reyes

Deadline for manuscript submissions

31 July 2026



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/254407

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)